Drug Trial Radar · NCT03288532
Renal Adjuvant MultiPle Arm Randomised Trial
Last checked: Nov 19, 2026Latest source record: Sep 7, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,750
Planned (sponsor's estimate)
Start
Jul 19, 2018
Primary completion
Jul 1, 2024
Study completion Dec 1, 2034
Sponsor
- Lead sponsor
- University College, LondonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- AstraZeneca; Kidney Cancer UK; Cancer Research UK
- First posted
- Sep 20, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
RATIONALE: The current global standard of care after nephrectomy for localised RCC therefore remains active monitoring (i.e., observation by clinical and radiological means). 30-40% patients with initially localised RCC develop metastatic disease following nephrectomy. Need for adjuvant therapy is most marked in the high risk population where outcomes are predictably poor. However, the risk of recurrence in patients who are of intermediate risk of recurrence is not insignificant. Unfortunately, despite showing efficacy in advanced RCC, the results in the adjuvant setting, so far, are inconclusive. AIM: RAMPART is a phase III Multi-Arm Multi-Stage randomised controlled platform trial, initiated with three arms. The trial is assessing if durvalumab monotherapy or the combination of durvalumab and tremelimumab can improve Disease Free Survival (DFS) or Overall Survival (OS) compared to the current global standard-of-care (active monitoring). At the start of recruitment, patients with Leibovich scores 3 to 11 will be eligible for randomisation. Accrual of intermediate risk patients (Leibovich scores 3 5) will stop after 3 years or when intermediate risk patients contribute 25% of the total accrual target, whichever is earlier. Recruitment of patients with Leibovich scores 6 to 11 will continue until the accrual target is reached.
Conditions
- Renal Cell Carcinoma
Interventions
DurvalumabDrug
controlled infusion via an infusion pump into a peripheral or central vein
TremelimumabDrug
controlled infusion via an infusion pump into a peripheral or central vein
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease Free Survival (DFS): Arm C vs ATime frame: 6.25 years
- Disease Free Survival (DFS): Arm B vs ATime frame: 10.54 years
- Overall Survival (OS): Arm C vs A (high risk patients only)Time frame: 13.25 years
- Overall Survival (OS): Arm B vs A (high risk patients only)Time frame: 20.5 years
Locations
35 sites in 1 country. Site status is shown where the registry gives one.
Aberdeen Royal Infirmary
Aberdeen, United Kingdom · Recruiting
Ysbyty Gwynedd
Bangor, United Kingdom · Recruiting
Royal Bournemouth Hospital
Bournemouth, United Kingdom · Recruiting
Bristol Haematology and Oncology Centre
Bristol, United Kingdom · Recruiting
Addenbrookes Hospital
Cambridge, United Kingdom · Recruiting
Velindre Cancer Centre
Cardiff, United Kingdom · Recruiting
Broomfield Hospital
Chelmsford, United Kingdom · Recruiting
Cheltenham General Hospital
Cheltenham, United Kingdom · Recruiting
Colchester General Hospital
Colchester, United Kingdom · Recruiting
University Hospital Coventry & Warwickshire
Coventry, United Kingdom · Recruiting
Western General Hospital
Edinburgh, United Kingdom · Recruiting
Beatson West of Scotland Cancer Centre
Glasgow, United Kingdom · Recruiting
Diana Princess of Wales Hospital
Grimsby, United Kingdom · Recruiting
Castle Hill Hospital
Hull, United Kingdom · Recruiting
Raigmore Hospital
Inverness, United Kingdom · Recruiting
St James University Hospital
Leeds, United Kingdom · Recruiting
Leicester Royal Infirmary
Leicester, United Kingdom · Recruiting
Clatterbridge Cancer Centre
Liverpool, United Kingdom · Recruiting
St Bartholomew's Hospital
London, United Kingdom · Recruiting
Mount Vernon Hospital
London, United Kingdom · Recruiting
Royal Free Hospital
London, United Kingdom · Recruiting
Guy's Hospital
London, United Kingdom · Recruiting
Royal Marsden Hospital
London, United Kingdom · Recruiting
Charing Cross Hospital
London, United Kingdom · Recruiting
The Christie
Manchester, United Kingdom · Recruiting
Nottingham University Hospital
Nottingham, United Kingdom · Recruiting
Churchill Hospital
Oxford, United Kingdom · Recruiting
Glan Clwyd Hospital
Rhyl, United Kingdom · Recruiting
Scunthorpe General Hospital
Scunthorpe, United Kingdom · Recruiting
Weston Park Hospital
Sheffield, United Kingdom · Recruiting
South Tyneside District Hospital
South Shields, United Kingdom · Recruiting
Southend University Hospital
Southend-on-Sea, United Kingdom · Recruiting
Sunderland Royal Hospital
Sunderland, United Kingdom · Recruiting
Royal Marsden Hospital
Sutton, United Kingdom · Recruiting
Torbay Hospital
Torquay, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.